CT-1 knockout versus wild-type mice under normal diet, high-cholesterol diet, or streptozotocin- (STZ-) induced diabetes
Treatment with rat recombinant CT-1 (0.2 mg/kg per day for 6–10 days) versus vehicle
CT-1 knockout mice develop obesity, insulin resistance, and hypercholesterolemia despite a reduced caloric intake as compared to wild type. Acute treatment with CT-1 decreased blood glucose in an insulin-independent manner as compared to vehicle. Chronic treatment with CT-1 treatment reduced food intake, enhanced energy expenditure, and induced white adipose tissue remodeling as compared to vehicle